.jpg)
.jpeg)
Renel Cell Carcinoma
Renal cell carcinoma (RCC) is the most common type of kidney cancer, arising from the cells lining the small tubes within the kidney. It often presents as a solid mass or tumor within the kidney and can spread to other organs if not treated early.
Partial nephrectomy, also known as nephron-sparing surgery, is a surgical procedure where only the tumor and a portion of the kidney tissue surrounding it are removed, rather than the entire kidney. This approach is preferred when the tumor is small and located in a favorable position within the kidney, allowing preservation of kidney function.
Partial nephrectomy is considered the gold standard treatment for small renal cell carcinomas because it offers equivalent cancer control rates compared to radical nephrectomy (removal of the entire kidney) while preserving more healthy kidney tissue. Preserving kidney function is particularly important for patients with a single kidney or pre-existing kidney disease.
After partial nephrectomy, patients typically undergo regular follow-up appointments and imaging studies to monitor for recurrence and assess kidney function. Adjuvant therapies such as targeted therapy or immunotherapy may be recommended depending on the stage and characteristics of the RCC.
Partial nephrectomy, also known as nephron-sparing surgery, is a surgical procedure where only the tumor and a portion of the kidney tissue surrounding it are removed, rather than the entire kidney. This approach is preferred when the tumor is small and located in a favorable position within the kidney, allowing preservation of kidney function.
Partial nephrectomy is considered the gold standard treatment for small renal cell carcinomas because it offers equivalent cancer control rates compared to radical nephrectomy (removal of the entire kidney) while preserving more healthy kidney tissue. Preserving kidney function is particularly important for patients with a single kidney or pre-existing kidney disease.
After partial nephrectomy, patients typically undergo regular follow-up appointments and imaging studies to monitor for recurrence and assess kidney function. Adjuvant therapies such as targeted therapy or immunotherapy may be recommended depending on the stage and characteristics of the RCC.